Stockholm3 Detects 90% of Significant Prostate Cancers, Beating PSA's 74%
Updated
Updated · 2 Minute Medicine · Jun 22
Stockholm3 Detects 90% of Significant Prostate Cancers, Beating PSA's 74%
3 articles · Updated · 2 Minute Medicine · Jun 22
Summary
In 12,670 men aged 50-74, Stockholm3 identified 400 of 443 clinically significant prostate cancers over 2 years, versus 327 detected by PSA alone.
That translated to 90% sensitivity for Stockholm3 against 74% for PSA, while specificity stayed similar at 89% versus 90% and false-positive rates were close at 11% versus 10%.
Per 1,000 men screened, Stockholm3 found more significant cancers than PSA—31.6 versus 25.8—and missed far fewer cases, 3.4 versus 9.2.
The randomized trial suggests the multivariable test—combining PSA, biomarkers, genetic risk and clinical factors—could improve screening without materially increasing unnecessary biopsies.
Researchers said longer-term follow-up is still needed, as participation was low and the cohort was limited to the Stockholm region.
Stockholm3 detects more deadly cancers than PSA. Is this the end of the decades-long screening debate?
By adding genetic risk to a blood test, screening accuracy soared. Is our DNA the key to the future of cancer detection?
Stockholm3 Blood Test Revolutionizes Prostate Cancer Screening: 90% Detection Rate, Fewer Biopsies, and Global Adoption Challenges
Overview
The Stockholm3 blood test is showing strong promise for improving prostate cancer screening worldwide. Backed by robust validation, including a large study of over 12,000 men, Stockholm3 can identify up to 90% of clinically significant prostate cancers. It detects more than twice as many high-risk cases as the traditional PSA test, which often misses aggressive cancers. These results highlight Stockholm3’s potential to transform screening by finding more dangerous cancers earlier and more accurately, supporting its global expansion and offering hope for better patient outcomes.